Baird analyst Brian Skorney lowered the price target on Neurocrine Bio. (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Neurocrine Bio. (NBIX) PT Lowered to $102 at H.C. WainwrightDecember 13, 2018 11:09 AM Neurocrine Bio. (NBIX) PT Lowered to $105 at OppenheimerDecember 13, 2018 9:30 AM Neurocrine Bio. (NBIX) PT Lowered to $97 at JPMorganDecember 12, 2018 10:54 AM Neurocrine Bio. (NBIX) PT Lowered to $104 at Needham & CompanyDecember 12, 2018 10:48 AM Pre-Open Movers 12/12: (FOMX) (BTAI) (CORT) Higher; (SGYP) (NBIX) (PLAY) Lower (more...)December 12, 2018 9:30 AM Form 8-K NEUROCRINE BIOSCIENCES For: Dec 12December 12, 2018 8:01 AM Neurocrine Biosciences (NBIX) to Resume Trading at 8 am ETDecember 12, 2018 7:34 AM Neurocrine Biosciences (NBIX) Says Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette SyndromeDecember 12, 2018 7:31 AM Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette SyndromeDecember 12, 2018 7:30 AM Neurocrine Biosciences (NBIX) Halted, News PendingDecember 12, 2018 7:25 AM